Prokinetic agents (natural or pharmaceutical) taken between meals stimulate the MMC
All reconstitution solution products are stored under Controlled Room Temperature (CRT) conditions prior to shipment
It remains an investigational drug currently being evaluated in Phase 3 clinical trials by Eli Lilly for the treatment of: Obesity (without diabetes) Type 2 diabetes Nonalcoholic fatty liver disease (NAFLD/NASH) Projected Approval Timeline Based on Phase 2 success and accelerated trials, Retatrutide could receive FDA approval as early as 2026 Eli Lilly is positioning it to directly compete with Tirzepatide (Mounjaro) and Semaglutide (Wegovy) Expected to be administered as a once-weekly injection Not Available for Research or Off-Label Use Retatrutide is not legally available on the gray market No legitimate research chemical suppliers offer it any listings claiming to sell Retatrutide are likely counterfeit or misbranded Because of its complex multi-receptor structure, DIY compounding is extremely risky and discouraged Athletic Use and WADA Considerations Like other GLP-1 agonists, Retatrutide is not currently banned by WADA However, its performance-enhancing effects (fat loss, appetite suppression, metabolic acceleration) could put it under scrutiny in the future Athletes in tested federations should proceed cautiously once the drug is commercialized Until Retatrutide clears regulatory approval, its use remains confined to clinical trial settings
Content current as of April 22, 2026
Most Massachusetts private plans, such as Blue Cross Blue Shield, cover Ozempic for Type 2 diabetes, but not Wegovy or other GLP-1s prescribed solely for weight loss
On the other hand, Saxenda is specifically approved for weight management in adults and children aged 12 years and older who are obese or overweight and have weight-related medical problems
